Economic benefit and competitive advantage from commercial adoption of an innovative non-invasive delivery method for drugs and vaccines

Impact: Impact - for External PortalEconomic and commerce, Health and welfare - new products, guidelines and services


Research into non-ionic surfactant vesicles (NIV) led to the development of an innovative platform system for delivery of vaccines and drugs, either through oral administration or inhalation. The technology was licensed to a US company, VBI Vaccines in 2008 and led to product development in that company. The adoption of the technology supported the creation of 35 FTE jobs in US/Canada and attracted 50% of the licensor company's Series A VC investment (approximately $18M). It was also adopted by Morvus Technology Ltd. (2010). The University collaborated with Biovaxpahrma Ltd to create a new biotechnology spin out Inhalosome-C, which was awarded a £196k TSB grant in December 2012. The technology is currently being used in commercial R&D in two further companies, Aptuit Ltd and Philips Respiratory Drug Delivery.

Category of impact

  • Economic and commerce
  • Health and welfare - new products, guidelines and services

    Research areas

  • REF2014 impact case study

View graph of relations